Previous 10 | Next 10 |
The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders. All cust...
ICON Public Limited (ICLR) has entered into an agreement with the privately held clinical-stage biotech company, Cytocom to manage the company’s Phase 3 clinical trial for its lead drug candidate, CYTO-201 in Crohn's disease."CYTO-201 is the program's lead clinical asset and we are ple...
Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-19 PR Newswire FORT COLLINS, Colo. , Feb. 16, 2021 /PRNewswire/ -- Cytocom, Inc. , a leading biopharmaceutical company creating first second...
New solutions enable enhanced delivery, tracking and management of drug safety reporting and medical questions from sites ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industr...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Dr. Steve Cutler, CEO of ICON plc, & Mr. Bre...
Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device ...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced the release of its first Environmental, Social and ...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Mr. Brendan Brennan, CFO of ICON plc, will prese...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2020 Q3 earnings call. For further details see: ICON Public Limited Company 2020 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Icon PLC (NASDAQ: ICLR) Q3 2020 Earnings Call Oct 22, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Icon PLC (ICLR) Q3 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 20...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclus...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...